Search hospitals
>
Pennsylvania
>
Pittsburgh
Children's Hospital of Pittsburgh of UPMC
Claim this profile
Pittsburgh, Pennsylvania 15224
Global Leader in Brain Tumor
Global Leader in Solid Tumors
Conducts research for Cancer
Conducts research for Central Nervous System Tumor
Conducts research for Leukemia
907 reported clinical trials
83 medical researchers
Summary
Children's Hospital of Pittsburgh of UPMC is a medical facility located in Pittsburgh, Pennsylvania. This center is recognized for care of Brain Tumor, Solid Tumors, Cancer, Central Nervous System Tumor, Leukemia and other specialties. Children's Hospital of Pittsburgh of UPMC is involved with conducting 907 clinical trials across 1,123 conditions. There are 83 research doctors associated with this hospital, such as Jean M. Tersak, Andrew Bukowinski, Adam Olson, and James Felker, MD.
Area of expertise
Brain Tumor
Children's Hospital of Pittsburgh of UPMC has run 116 trials for Brain Tumor. Some of their research focus areas include:
Solid Tumors
Children's Hospital of Pittsburgh of UPMC has run 106 trials for Solid Tumors. Some of their research focus areas include:
Top PIs
Jean M. Tersak
Children's Hospital of Pittsburgh of UPMC
8 years of reported clinical research
Andrew Bukowinski
Children's Hospital of Pittsburgh of UPMC
10 years of reported clinical research
Adam Olson
UPMC-Shadyside Hospital
1 year of reported clinical research
James Felker, MD
Children's Hospital of Pittsburgh of UPMC
6 years of reported clinical research
Clinical Trials running at Children's Hospital of Pittsburgh of UPMC
Cancer
Burkitt Lymphoma
Leukemia
Testicular cancer
Acute Lymphoblastic Leukemia
Acute Leukemia
Brain Cancer
Cystic Fibrosis
Crohn's Disease
Neuroblastoma
Chemotherapy
for Cancer
This phase III trial studies how well active surveillance help doctors to monitor subjects with low risk germ cell tumors for recurrence after their tumor is removed. When the germ cell tumor has spread outside of the organ in which it developed, it is considered metastatic. Chemotherapy drugs, such as bleomycin, carboplatin, etoposide, and cisplatin, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. The trial studies whether carboplatin or cisplatin is the preferred chemotherapy to use in treating metastatic standard risk germ cell tumors.
Recruiting
2 awards
Phase 3
26 criteria
Triptorelin
for Cancer
This phase III trial compares the effect of giving triptorelin vs no triptorelin in preventing ovarian damage in adolescents and young adults (AYAs) with cancer receiving chemotherapy with an alkylating agents. Alkylating agents are part of standard chemotherapy, but may cause damage to the ovaries. If the ovaries are not working well or completely shut down, then it will be difficult or impossible to get pregnant in the future. Triptorelin works by blocking certain hormones and causing the ovaries to slow down or pause normal activity. The triptorelin used in this study stays active in the body for 24 weeks or about 6 months after a dose is given. After triptorelin is cleared from the body, the ovaries resume normal activities. Adding triptorelin before the start of chemotherapy treatment may reduce the chances of damage to the ovaries.
Recruiting
2 awards
Phase 3
4 criteria
DT2216 + Irinotecan
for Cancer
This phase I/II trial tests the safety, side effects and best dose of DT2216 in combination with irinotecan and how well it works in treating children, adolescents and young adults with solid tumors and fibrolamellar cancer that has come back after a period of improvement (relapsed) or that has not responded to previous treatment (refractory). DT2216 is an anti-apoptotic protein B-cell lymphoma-extra large targeted protein degrader. It may stop the growth of tumor cells by blocking Bcl-xL, a protein needed for tumor cell survival. Irinotecan is in a class of antineoplastic medications called topoisomerase I inhibitors. It blocks a certain enzyme needed for cell division and deoxyribonucleic acid repair and may kill tumor cells. Giving DT2216 in combination with irinotecan may be safe, tolerable, and/or effective in treating children, adolescents and young adults with relapsed or refractory solid tumors or fibrolamellar cancer.
Recruiting
1 award
Phase 1 & 2
7 criteria
Similar Hospitals nearby
Frequently asked questions
What kind of research happens at Children's Hospital of Pittsburgh of UPMC?
Children's Hospital of Pittsburgh of UPMC is a medical facility located in Pittsburgh, Pennsylvania. This center is recognized for care of Brain Tumor, Solid Tumors, Cancer, Central Nervous System Tumor, Leukemia and other specialties. Children's Hospital of Pittsburgh of UPMC is involved with conducting 907 clinical trials across 1,123 conditions. There are 83 research doctors associated with this hospital, such as Jean M. Tersak, Andrew Bukowinski, Adam Olson, and James Felker, MD.
Where is Children's Hospital of Pittsburgh of UPMC located?
The Children's Hospital of Pittsburgh of UPMC is located at 4401 Penn Ave, Pittsburgh, PA 15224, United States.
Who should I call to ask about financial aid or insurance network?
**Children's Hospital of Pittsburgh of UPMC Financial Assistance:** - Contact the Business Office at 412-692-7600, available from 8 a.m. to 4 p.m., Monday through Friday. **UPMC Western Maryland Insurance Hotline:** - For insurance-related inquiries, call 240-964-8111.
What insurance does Children's Hospital of Pittsburgh of UPMC accept?
The Children's Hospital of Pittsburgh of UPMC accepts a wide range of health insurance plans. This includes commercial insurance plans such as Aetna, Capital Blue Cross, Cigna Health, and United HealthCare, among others. Government insurance plans accepted include Military insurances like VA and Tricare, Medicare plans such as Aetna Medicare Advantage and Highmark Freedom Blue, and Medicaid plans like Aetna Better Health and UPMC for You.
What awards or recognition has Children's Hospital of Pittsburgh of UPMC received?
UPMC Children's Hospital of Pittsburgh supports research through various grants, including: - Pilot grants: $50,000 per year for two years. - Trainee grants: $50,000 per year for two years. - The Ghazi Lab has received research grants from the American Federation for Aging Research and the University of Pittsburgh. - The Children's Neuroscience Institute offers annual Interdisciplinary Neuroscience Awards (INA) of up to $50,000, favoring projects that involve multi-omic platforms, induced pluripotent stem cell technology, bioinformatics, and molecular imaging approaches.
Unbiased Results
We believe in providing patients with all the options.
Your Data Stays Your Data
We only share your information with the clinical trials you're trying to access.
Verified Trials Only
All of our trials are run by licensed doctors, researchers, and healthcare companies.
Unbiased Results
We believe in providing patients with all the options.
Your Data Stays Your Data
We only share your information with the clinical trials you're trying to access.
Verified Trials Only
All of our trials are run by licensed doctors, researchers, and healthcare companies.